Partner Jeffrey Fessler Represents Synergy Pharmaceuticals Inc. on $89.8 Million Registered Direct Offering of Common Stock
Press Release – New York, NY – May 6, 2016 – Securities and corporate law firm Sichenzia Ross Friedman Ference LLP is pleased to announce that the Firm has represented Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, on a registered direct offering of 29,948,334 shares of the Company’s common stock at a public offering price per share of $3.00 without an underwriter or placement agent.
Synergy raised $89.8 million in gross proceeds.
The Sichenzia Ross Friedman Ference LLP team was led by Partners Jeffrey J. Fessler and Stephen A. Cohen.
Visit SRFK's LinkedIn page
Latest posts by Sichenzia Ross Ference Kesner LLP (see all)
- Sichenzia Ross Ference Kesner LLP Congratulates AYTU Biosciences, Inc., on NASDAQ Uplisting - October 19, 2017
- Sichenzia Ross Ference Kesner LLP Represents Joseph Gunnar and Fordham Financial Management in $6.75 Million Registered Direct Offering of Common Stock of Ampio Pharmaceuticals, Inc. - October 18, 2017
- Sichenzia Ross Ference Kesner LLP Advises US Gold Corp. on $2.5 Million Public Offering - October 13, 2017